R
RhyGaze
Gene therapy innovator restoring vision in blindness through cone optogenetics
About RhyGaze
RhyGaze AG, based in Basel, Switzerland, is pioneering a transformative approach in the field of gene therapy, specifically targeting blindness caused by retinal diseases. The company focuses on cone optogenetics, a cutting-edge technique that introduces a new light sensor gene to cone cells in the retina, which have lost their sensitivity to light. This method aims to restore the ability of these cells to detect light, potentially revolutionizing vision restoration for patients. RhyGaze serves the healthcare sector, particularly targeting patients with retinal diseases, and operates within the biotech market. The business model involves advancing its gene therapy solutions through clinical trials, with the recent CHF10 million seed funding being allocated to transition the therapy to a third-party manufacturing organization and to conduct necessary studies for initiating human clinical trials. The company generates revenue through partnerships and funding from venture capital firms, including BioGeneration Ventures and the Novartis Venture Fund. RhyGaze is a spin-out from the Institute of Molecular and Clinical Ophthalmology in Basel, contributing significantly to the local biotech ecosystem.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Basel, Switzerland
- Employees
- 14
- Open positions
- 1
- Dealroom signal
- 59.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Gene Therapy, Spinout, Biotech and Pharma, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jan 2025 | $86M | $344M | BioGeneration Ventures · F-Prime · Novartis Venture Fund · GV | ↗ |
| SEEDOther financing | Jul 2024 | $11M | $44M | Novartis Venture Fund · BioGeneration Ventures | ↗ |
Growth signals
Latest recorded traffic for RhyGaze is 2.5K monthly website visits, up 66.7% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
RhyGaze in the Basel ecosystem
The RhyGaze office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Novartis Venture Fund
BioGeneration Ventures
Series A3 investors entered at this stage
Other known investors1 additional known investor
University of Basel
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RhyGaze on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RhyGaze’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.












